 |
|
Use of Antidepressants and Rates of Hip Bone Loss in Older WomenThe Study of Osteoporotic Fractures
Susan J. Diem, MD, MPH;
Terri L. Blackwell, MA;
Katie L. Stone, PhD;
Kristine Yaffe, MD;
Elizabeth M. Haney, MD;
Michael M. Bliziotes, MD;
Kristine E. Ensrud, MD, MPH
Arch Intern Med. 2007;167(12):1240-1245.
Background Serotonin transporters have recently been described in bone, raising the possibility that medications that block serotonin reuptake could affect bone metabolism.
Methods We assessed current use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) and obtained serial bone mineral density (BMD) measurements in a cohort of 2722 older women (mean age, 78.5 years) participating in the Study of Osteoporotic Fractures, a prospective cohort study of community-dwelling women. Hip BMD was measured at the sixth examination and an average of 4.9 years later at the eighth examination. We categorized women as nonusers (used no SSRIs or TCAs at either examination; n = 2406), SSRI users (used SSRIs but no TCAs at either examination; n = 198), or TCA users (used TCAs but no SSRIs at either examination; n = 118). Depressive symptoms were identified using a cutoff score of at least 6 on the Geriatric Depression Scale.
Results After adjustment for potential confounders, including the Geriatric Depression Scale score, mean total hip BMD decreased 0.47% per year in nonusers compared with 0.82% in SSRI users (P<.001) and 0.47% in TCA users (P = .99). Higher rates of bone loss were also observed at the 2 hip subregions for SSRI users. Results were not substantially altered when women who scored at least 6 on the Geriatric Depression Scale were excluded from the analysis.
Conclusion Use of SSRIs but not TCAs is associated with an increased rate of bone loss at the hip in this cohort of older women.
Author Affiliations: Department of Medicine and Division of Epidemiology, University of Minnesota (Drs Diem and Ensrud), and Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Medical Center (Dr Ensrud), Minneapolis, Minn; California Pacific Medical Center Research Institute, San Francisco (Ms Blackwell and Dr Stone); Departments of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California–San Francisco (Dr Yaffe); Department of Psychiatry, San Francisco Veterans Affairs Medical Center, San Francisco (Dr Yaffe); and Department of Medicine, Oregon Health Sciences Center, Portland (Drs Haney and Bliziotes).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Selective Serotonin Reuptake Inhibitors and Osteoporosis: Pathomechanism and Clinical Relevance Remain to Be Established
Olaf Schulte-Herbrüggen and Ion Anghelescu
Arch Intern Med. 2008;168(1):110.
EXTRACT
| FULL TEXT
Concerns About Bone Safety of Tricyclic Antidepressant Therapy
Wee-Shiong Lim and Mark Chan
Arch Intern Med. 2008;168(4):435-436.
EXTRACT
| FULL TEXT
Concerns About Bone Safety of Tricyclic Antidepressant Therapy—Reply
Susan Diem, Terri Blackwell, Katie L. Stone, Kristine Yaffe, Elizabeth Haney, Michael Bliziotes, and Kristine E. Ensrud
Arch Intern Med. 2008;168(4):436.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Mend the Mind, but Mind the Bones!: Balancing Benefits and Potential Skeletal Risks of Serotonin Reuptake Inhibitors
Kenneth Saag
Arch Intern Med. 2007;167(12):1231-1232.
EXTRACT
| FULL TEXT
Association of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Elizabeth M. Haney, Benjamin K. S. Chan, Susan J. Diem, Kristine E. Ensrud, Jane A. Cauley, Elizabeth Barrett-Connor, Eric Orwoll, M. Michael Bliziotes, and for the Osteoporotic Fractures in Men Study Group
Arch Intern Med. 2007;167(12):1246-1251.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Health status and risk for depression among the elderly: a meta-analysis of published literature
Chang-Quan et al.
Age Ageing 2009;0:afp187v1-afp187.
ABSTRACT
| FULL TEXT
Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret et al.
J Psychopharmacol 2009;23:967-974.
ABSTRACT
Serotonin Rising
Anderson et al.
NEJM 2009;360:2580-2582.
FULL TEXT
Wnt Signaling, LRP5 and Gut Serotonin: Have We Been Targeting the Right Pathway for the Wrong Reasons?
Baron
IBMS BoneKEy 2009;6:86-93.
FULL TEXT
Risk of Fractures with Selective Serotonin-Reuptake Inhibitors or Tricyclic Antidepressants
Ginzburg and Rosero
The Annals of Pharmacotherapy 2009;43:98-103.
ABSTRACT
| FULL TEXT
Depression, Antidepressants, and Bone Mineral Density in a Population-Based Cohort
Mezuk et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:1410-1415.
ABSTRACT
| FULL TEXT
Non-estrogen-based treatments for menopausal symptoms
Writing Group for the British Menopause Society Co et al.
Menopause Int 2008;14:88-90.
ABSTRACT
| FULL TEXT
Concerns About Bone Safety of Tricyclic Antidepressant Therapy--Reply
Diem et al.
Arch Intern Med 2008;168:436-436.
FULL TEXT
Concerns About Bone Safety of Tricyclic Antidepressant Therapy
Lim and Chan
Arch Intern Med 2008;168:435-436.
FULL TEXT
Selective Serotonin Reuptake Inhibitors and Osteoporosis: Pathomechanism and Clinical Relevance Remain to Be Established
Schulte-Herbruggen and Anghelescu
Arch Intern Med 2008;168:110-110.
FULL TEXT
Buspirone for Autistic Disorder in a Woman with an Intellectual Disability
Brahm et al.
The Annals of Pharmacotherapy 2008;42:131-137.
ABSTRACT
| FULL TEXT
Mend the Mind, but Mind the Bones!: Balancing Benefits and Potential Skeletal Risks of Serotonin Reuptake Inhibitors
Saag
Arch Intern Med 2007;167:1231-1232.
FULL TEXT
Association of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Haney et al.
Arch Intern Med 2007;167:1246-1251.
ABSTRACT
| FULL TEXT
|
